As Insulin Producers Shift Focus, rBIO Emerges to Combat Shortages
In a time when many major insulin manufacturers are focusing on profitability with the introduction of newer GLP-1 drugs, rBIO is stepping up to address a looming crisis in insulin access. While recent efforts to reduce the prices of older insulin products have been made, these changes neglect a significant portion of patients reliant on specific formulations that may soon cease to exist. The landscape has become increasingly troubling for individuals managing diabetes, particularly with critical products like Novo Nordisk's Levemir being discontinued.
In response, rBIO has successfully completed the preclinical phase for its first biosimilar insulin, branded as R-biolin. This move signifies a promising advancement in the quest to provide affordable and reliable insulin alternatives. The company's CEO, Cameron Owen, emphasized the urgent need for a steady supply of accessible insulin as they look to establish their presence in the market.
"We aim to ensure that no patient faces a lack of insulin options due to industry shifts focused on profit margins rather than care," Owen stated. rBIO's R-biolin has shown bioequivalence to Novo Nordisk's Novolin® R in preclinical animal studies, leading the company to prepare for significant scale-ups and upcoming human trials. This progress marks a considerable step towards meeting the requirements of those living with diabetes, particularly as the insulin landscape changes.
The preclinical study was carried out by Innospec, a leader in contract research, and confirmed that R-biolin demonstrated similar efficacy in reducing blood glucose levels compared to Novolin. Dr. Viswanathan, director of Innospec Bioresearch, noted that their initial findings of R-biolin mirror the trusted profile of Novolin.
Additionally, rBIO's development strategy is aimed at addressing the unmet needs arising from discontinuations in the market. By prioritizing the production of biosimilars for less profitable or phased-out insulins, rBIO is paving the way for high-quality alternatives at a fraction of the cost—an approach that challenges the traditional focus of the industry.
Owen further mentioned that the company is already in development for a Levemir biosimilar to counter the critical shortage resulting from its withdrawal. "Our goal is to bring this product to market swiftly, ensuring that all patients have access to the insulin they need," he declared. rBIO is tapping into innovative production technologies to drive down costs and bolster the availability of essential insulin options for those who rely on them.
Alison Smart, founder of the Alliance to Protect Insulin Choice, praised rBIO's dedication to patient welfare amidst rising concerns over the industry's profit-first mentality. "The challenges diabetes patients face today necessitate solutions like rBIO's biosimilars, which offer reassurance and a path towards stabilization in insulin access," she said.
With the validation of R-biolin complete, rBIO is on the lookout for partnerships to accelerate the transition from clinical studies to commercial production. The company is deeply committed to making insulin not only accessible but also affordable, thereby ensuring that lives of those affected by diabetes are safeguarded. Final contact points to learn more about rBIO and their mission can be found by visiting rBIO.com or reaching out to CEO Cameron Owen directly.
In summary, as the demand for insulin remains steady against a backdrop of manufacturer transitions prioritizing profit over access, rBIO stands ready to fill the gaps. Their innovative approach to biosimilar insulin production is set to lead a new wave of solutions aimed explicitly at enhancing patient care and reducing the financial burden posed by diabetes management. The quest for affordable insulin remains urgent and necessary as we forge ahead in this transformative healthcare landscape.
In response, rBIO has successfully completed the preclinical phase for its first biosimilar insulin, branded as R-biolin. This move signifies a promising advancement in the quest to provide affordable and reliable insulin alternatives. The company's CEO, Cameron Owen, emphasized the urgent need for a steady supply of accessible insulin as they look to establish their presence in the market.
"We aim to ensure that no patient faces a lack of insulin options due to industry shifts focused on profit margins rather than care," Owen stated. rBIO's R-biolin has shown bioequivalence to Novo Nordisk's Novolin® R in preclinical animal studies, leading the company to prepare for significant scale-ups and upcoming human trials. This progress marks a considerable step towards meeting the requirements of those living with diabetes, particularly as the insulin landscape changes.
The preclinical study was carried out by Innospec, a leader in contract research, and confirmed that R-biolin demonstrated similar efficacy in reducing blood glucose levels compared to Novolin. Dr. Viswanathan, director of Innospec Bioresearch, noted that their initial findings of R-biolin mirror the trusted profile of Novolin.
Additionally, rBIO's development strategy is aimed at addressing the unmet needs arising from discontinuations in the market. By prioritizing the production of biosimilars for less profitable or phased-out insulins, rBIO is paving the way for high-quality alternatives at a fraction of the cost—an approach that challenges the traditional focus of the industry.
Owen further mentioned that the company is already in development for a Levemir biosimilar to counter the critical shortage resulting from its withdrawal. "Our goal is to bring this product to market swiftly, ensuring that all patients have access to the insulin they need," he declared. rBIO is tapping into innovative production technologies to drive down costs and bolster the availability of essential insulin options for those who rely on them.
Alison Smart, founder of the Alliance to Protect Insulin Choice, praised rBIO's dedication to patient welfare amidst rising concerns over the industry's profit-first mentality. "The challenges diabetes patients face today necessitate solutions like rBIO's biosimilars, which offer reassurance and a path towards stabilization in insulin access," she said.
With the validation of R-biolin complete, rBIO is on the lookout for partnerships to accelerate the transition from clinical studies to commercial production. The company is deeply committed to making insulin not only accessible but also affordable, thereby ensuring that lives of those affected by diabetes are safeguarded. Final contact points to learn more about rBIO and their mission can be found by visiting rBIO.com or reaching out to CEO Cameron Owen directly.
In summary, as the demand for insulin remains steady against a backdrop of manufacturer transitions prioritizing profit over access, rBIO stands ready to fill the gaps. Their innovative approach to biosimilar insulin production is set to lead a new wave of solutions aimed explicitly at enhancing patient care and reducing the financial burden posed by diabetes management. The quest for affordable insulin remains urgent and necessary as we forge ahead in this transformative healthcare landscape.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.